The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).
Melissa Alsina
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Paul Gerard Guy Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium; Novartis
Robert L. Schlossman
Other Remuneration - Celgene; Millennium
Donna M. Weber
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Steven E. Coutre
No relevant relationships to disclose
Cristina Gasparetto
Consultant or Advisory Role - Celgene; Millennium; Novartis (I)
Honoraria - Novartis (I)
Sutapa Mukhopadhyay
Employment or Leadership Position - Novartis
Michael S. Ondovik
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Mahmudul H Khan
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Carole S. Paley
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi